KALA BIO Inc

NASDAQ:KALAUnited States

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Contact Information

Headquarters

1167 Massachusetts AvenueARLINGTON, MA, United States 02476

Phone

781-996-5252

Fax

781-642-0399

Executives

Chairman of the Board, Chief Executive Officer

Mark Iwicki

President, Chief Operating Officer

Todd Bazemore

Chief Financial Officer, Treasurer

Mary Reumuth

Chief Compliance Officer, General Counsel, Corporate Secretary

Eric Trachtenberg

Head of Research and Development, Chief Medical Officer

Kim Brazzell